In silico prediction of potential inhibitors for SARS-CoV-2 Omicron variant using molecular docking and dynamics simulation-based drug repurposing

EAR Mohamed, IM Abdel-Rahman, MEA Zaki… - Journal of Molecular …, 2023 - Springer
Abstract Background In November 2021, variant B. 1.1. 529 of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) was identified by the World Health Organization …

Discovery of SARS-CoV-2 Antiviral Drugs Through Large-Scale Virtual Screening of FDA-Approved Drugs

W Ezzemani, A Ouladlahsen, H Altawalah… - Advances in Antiviral …, 2024 - Springer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent
responsible for the viral pneumonia outbreak of coronavirus disease 2019 (COVID-19) …

COVID-19: How effective are the repurposed drugs and novel agents in treating the infection?

C Suet-May, K Sin-Yee, L Jia-Qing… - Sudan Journal of …, 2022 - ajol.info
Abstract Coronavirus disease 2019 (COVID-19) induced by the severe acute respiratory
syndrome coronavirus type 2 (SARS-CoV-2) has impacted the lives and wellbeing of many …

Therapeutic potential of plant secondary metabolites in treatment of respiratory viral diseases: A review

S Sharma, S Sharma, A Rai, S Singh… - Medicinal Plants …, 2022 - indianjournals.com
Respiratory viral infections are a major public health concern because of their global
occurrence, ease of spread and considerable morbidity and mortality. Medical treatments for …

Comparación de la patogenia, tratamiento y vacunas entre la Peritonitis Infecciosa Felina y la COVID-19

A Gómez del Pulgar Pitar, MC Simón Valencia - zaguan.unizar.es
La Peritonitis Infecciosa Felina (PIF) es una enfermedad mortal producida por Coronavirus
Felinos (FCoV) que junto a con una respuesta inmunopatológica alterada desencadena un …